Photo Release -- Biopharmaceutical Company Seeks New Sources of Corn Lily
22 juin 2011 10h00 HE
|
Infinity Pharmaceuticals, Inc.
SALT LAKE CITY and BOISE, Idaho, June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company, is seeking new sources of a plant commonly known as...
Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway
22 juin 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small...
Infinity Reports First Quarter 2011 Financial Results
10 mai 2011 16h00 HE
|
Infinity Pharmaceuticals, Inc.
— Reaffirms 2011 Financial Guidance and Provides Additional Details —
— Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma
03 avr. 2011 13h36 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical...
Infinity Provides Company Update and Reports Fourth Quarter and Full-Year 2010 Financial Results
15 mars 2011 16h00 HE
|
Infinity Pharmaceuticals, Inc.
IPI-926 Advancing in Two Phase 2 Trials, Underscoring Pipeline Momentum
Cash Runway Into 2014 Enables Advancement of Product Candidates to
Key Inflection Points
Company Changes Accounting...